Education
About Us
Working with TipRanks
Follow Us
Stayble Therapeutics AB (DE:4K4)
:4K4
4K4 Stock Chart & Stats
Day’s Range― - ―
52-Week Range€0.02 - €0.08
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€2.49M
Enterprise Value€44.92M
Total Cash (Recent Filing)€2.19M
Total Debt (Recent Filing)kr0.00
Price to Earnings (P/E)―
Beta-0.56
Next Earnings
Aug 26, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding64,359,795
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)3.72
Price to Sales (P/S)0.00
P/FCF Ratio-2.29
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
4K4 FAQ
What was Stayble Therapeutics AB’s price range in the past 12 months?
Stayble Therapeutics AB lowest stock price was €0.02 and its highest was €0.08 in the past 12 months.
What is Stayble Therapeutics AB’s market cap?
Stayble Therapeutics AB’s market cap is €2.49M.
When is Stayble Therapeutics AB’s upcoming earnings report date?
Stayble Therapeutics AB’s upcoming earnings report date is Aug 26, 2025 which is in 57 days.
How were Stayble Therapeutics AB’s earnings last quarter?
Stayble Therapeutics AB released its earnings results on May 20, 2025. The company reported -€0.004 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.004.
Is Stayble Therapeutics AB overvalued?
According to Wall Street analysts Stayble Therapeutics AB’s price is currently Overvalued.
Does Stayble Therapeutics AB pay dividends?
Stayble Therapeutics AB does not currently pay dividends.
What is Stayble Therapeutics AB’s EPS estimate?
Stayble Therapeutics AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Stayble Therapeutics AB have?
Stayble Therapeutics AB has 64,359,795 shares outstanding.
What happened to Stayble Therapeutics AB’s price movement after its last earnings report?
Stayble Therapeutics AB reported an EPS of -€0.004 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Stayble Therapeutics AB?
Currently, no hedge funds are holding shares in DE:4K4
Company Description
Stayble Therapeutics AB
Stayble Therapeutics AB (publ) develops injectable treatment for chronic low back pain triggered by disc degeneration. The company develops STA363, a minimally invasive single injection of the drug into the disc that targets chronic low back pain. Stayble Therapeutics AB (publ) was incorporated in 2015 and is based in Gothenburg, Sweden.
Technical Analysis
Diagonal Bio AB
―
LIDDS AB
―
Lipigon Pharmaceuticals AB
―
CombiGene AB
―
QuiaPEG Pharmaceuticals Holding AB
―